ATE395067T1 - Verwendung von sulfatierten glykosaminoglykanen zur herbeiführung von effektiven wehen bei frauen - Google Patents

Verwendung von sulfatierten glykosaminoglykanen zur herbeiführung von effektiven wehen bei frauen

Info

Publication number
ATE395067T1
ATE395067T1 AT03700633T AT03700633T ATE395067T1 AT E395067 T1 ATE395067 T1 AT E395067T1 AT 03700633 T AT03700633 T AT 03700633T AT 03700633 T AT03700633 T AT 03700633T AT E395067 T1 ATE395067 T1 AT E395067T1
Authority
AT
Austria
Prior art keywords
pregnant woman
labor
myometrium
cervix
molecular weight
Prior art date
Application number
AT03700633T
Other languages
English (en)
Inventor
Gunvor Ekman-Ordeberg
Anders Malmstroem
Original Assignee
Dilafor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dilafor Ab filed Critical Dilafor Ab
Application granted granted Critical
Publication of ATE395067T1 publication Critical patent/ATE395067T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
AT03700633T 2002-01-02 2003-01-02 Verwendung von sulfatierten glykosaminoglykanen zur herbeiführung von effektiven wehen bei frauen ATE395067T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0200005A SE521676C2 (sv) 2002-01-02 2002-01-02 Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet

Publications (1)

Publication Number Publication Date
ATE395067T1 true ATE395067T1 (de) 2008-05-15

Family

ID=20286575

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03700633T ATE395067T1 (de) 2002-01-02 2003-01-02 Verwendung von sulfatierten glykosaminoglykanen zur herbeiführung von effektiven wehen bei frauen

Country Status (22)

Country Link
US (3) US7407945B2 (de)
EP (1) EP1461049B1 (de)
JP (1) JP4434741B2 (de)
KR (1) KR100958691B1 (de)
CN (1) CN100341518C (de)
AT (1) ATE395067T1 (de)
AU (1) AU2003201787B2 (de)
CA (1) CA2472093C (de)
CY (1) CY1108260T1 (de)
DE (1) DE60320931D1 (de)
DK (1) DK1461049T3 (de)
ES (1) ES2306852T3 (de)
HK (1) HK1076389A1 (de)
IL (2) IL162664A0 (de)
NO (1) NO332702B1 (de)
NZ (1) NZ533856A (de)
PL (1) PL206458B1 (de)
PT (1) PT1461049E (de)
SE (1) SE521676C2 (de)
SI (1) SI1461049T1 (de)
WO (1) WO2003055499A1 (de)
ZA (1) ZA200405015B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
WO2005007223A2 (en) * 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
ME02994B (de) * 2011-12-19 2018-10-20 Dilafor Ab Nicht antikoagulative glykosaminoglykane mit sich wiederholender disaccharideinheit und ihre medizinische verwendung
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
WO2013147689A1 (en) * 2012-03-26 2013-10-03 Dilafor Ab Combination treatment comprising sulphated glycosaminoglycans for inducing labor
CN104244957B (zh) * 2012-03-26 2017-11-17 迪乐方有限责任公司 用于治疗分娩停止的方法
EP2846810A4 (de) * 2012-05-08 2016-04-13 Dilafor Ab Behandlung von nachgeburtsblutungen mit chemisch modifiziertem heparin- oder heparansulfat und einem uterotonischen mittel
MX2015001508A (es) 2012-08-03 2015-04-08 Lfb Usa Inc El uso de antitrombina en la oxigenacion por membrana extracorporea.
KR20220142508A (ko) 2020-02-17 2022-10-21 딜라포 아베 자간전증 치료용 타폭시파린
WO2023213788A1 (en) 2022-05-03 2023-11-09 Dilafor Ab New medical use of tafoxiparin
EP4272749A1 (de) 2022-05-03 2023-11-08 Dilafor AB Neue medizinische verwendung von tafoxiparin

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
EP0209924A1 (de) * 1985-07-12 1987-01-28 Akzo N.V. Antithrombotikum auf Basis von Glykosaminoglykan, Verfahren zu dessen Herstellung und pharmazeutische Zusammensetzung
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5190926A (en) * 1987-01-28 1993-03-02 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
SE8702254D0 (sv) 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US6020322A (en) * 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5543389A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5256641A (en) * 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5280016A (en) 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
SE9302135D0 (sv) * 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
EP0831852B1 (de) * 1995-06-07 2006-11-29 Emory University Nucleoside mit anti-hepatitis b virus wirksamkeit
US6025335A (en) * 1995-09-21 2000-02-15 Lipitek International, Inc. L-Nucleoside Dimer Compounds and therapeutic uses
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
WO1998016559A1 (fr) * 1996-10-15 1998-04-23 Toray Industries, Inc. Agent de maturation des canaux cervicaux
JP4412756B2 (ja) 1998-02-26 2010-02-10 生化学工業株式会社 新規多糖誘導体、その製造法及びそれを有効成分とする医薬組成物
CA2335617C (en) * 1998-06-24 2009-12-15 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
IL127896A0 (en) * 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
JP2000309544A (ja) * 1999-02-25 2000-11-07 Seikagaku Kogyo Co Ltd 早産または流産防止剤および子宮頚管熟化抑制剤ならびにヒアルロニダーゼの阻害剤
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet

Also Published As

Publication number Publication date
SE521676C2 (sv) 2003-11-25
DK1461049T3 (da) 2008-09-15
PT1461049E (pt) 2008-08-22
ZA200405015B (en) 2005-08-31
AU2003201787A1 (en) 2003-07-15
US20120225843A1 (en) 2012-09-06
SE0200005D0 (sv) 2002-01-02
CN1612741A (zh) 2005-05-04
CA2472093C (en) 2011-02-22
AU2003201787B2 (en) 2008-02-28
CN100341518C (zh) 2007-10-10
DE60320931D1 (de) 2008-06-26
PL206458B1 (pl) 2010-08-31
CA2472093A1 (en) 2003-07-10
IL162664A (en) 2009-06-15
SI1461049T1 (sl) 2008-12-31
KR20040075917A (ko) 2004-08-30
IL162664A0 (en) 2005-11-20
EP1461049A1 (de) 2004-09-29
ES2306852T3 (es) 2008-11-16
EP1461049B1 (de) 2008-05-14
US20080269165A1 (en) 2008-10-30
PL370428A1 (en) 2005-05-30
US8524688B2 (en) 2013-09-03
HK1076389A1 (en) 2006-01-20
NO332702B1 (no) 2012-12-10
CY1108260T1 (el) 2014-02-12
US8207145B2 (en) 2012-06-26
SE0200005L (sv) 2003-07-03
KR100958691B1 (ko) 2010-05-18
WO2003055499A1 (en) 2003-07-10
US7407945B2 (en) 2008-08-05
NO20043190L (no) 2004-07-26
JP4434741B2 (ja) 2010-03-17
JP2005513148A (ja) 2005-05-12
NZ533856A (en) 2004-12-24
US20050075314A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
HK1076389A1 (en) Use of sulfated glycosaminoglycans for the manufacture of a pharmaceutical preparation for the prevention and treatment of slow progress of term labor
David‐Raoudi et al. Differential effects of hyaluronan and its fragments on fibroblasts: relation to wound healing
BRPI0511603A (pt) método para o tratamento de distúrbios do sangramento com a utilização de polissacarìdeos sulfatados
Kobayashi et al. Hyaluronic acid-specific regulation of cytokines by human uterine fibroblasts
Heyns et al. The glycosaminoglycans of the gubernaculum during testicular descent in the fetus
MY140581A (en) Compositions of marine botanicals to provide nutrition to aging and environmentally damaged skin
SA517381725B1 (ar) تركيبة قائمة على الأحماض الأمينية لاستعادة الإيلاستين الليفي في الأنسجة الضامة الأدمية
HU190687B (en) Process for preparing new antithrombotic of polysaccharide base further pharmaceutical compositions containing such substance as active material
Middeldorp Heparin: from animal organ extract to designer drug
DE602004018944D1 (de) Verwendung von abführmittel zur behandlung des reizdarmsyndroms
ES2141922T3 (es) Tiazepinonas de benzotiofeno, benzofurano e indol, oxazepinonas y diazepinonas usadas como inhibidores de la adherencia celular y del vih.
Thodiyil et al. Thromboprophylaxis in the cancer patient
MXPA06003234A (es) Citosinas protectoras de los tejidos para el tratamiento y prevencion de la sepsis y la formacion de adhesiones.
DE60143078D1 (de) Pax2 zur behandlung von nierenkrankheiten
WO2005060960A3 (en) Use of histamine to treat bone disease
RS51420B (en) HYPERSTRUCTURE AMYLOPECTIN FOR USE IN THE PROCEDURES OF SURGICAL OR THERAPEUTIC TREATMENT OF mammals OR IN THE PROCEDURES OF DIAGNOSIS, AND PARTICULARLY FOR USE AS A PLASMA VOLUME EXPANDER
Cohen et al. The essence trial: efficacy and safety of subcutaneous enoxaparin in unstable angina and non-Q-wave MI: a double-blind, randomized, parallel-group, multicenter study comparing enoxaparin and intravenous unfractionated heparin: methods and design
RU2014149230A (ru) Лечение послеродового кровотечения (прк)
ATE324905T1 (de) Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall
Bergqvist Update on in hospital venous thromboembolism prophylaxis
ATE400279T1 (de) Verwendung der sulfatierten polysacchariden zur behandlung von thrombosen
Trzaskoma et al. The use of heparin in the treatment of acute pancreatitis
Farr et al. The use of thromboembolic prophylaxis in oral and maxillofacial surgery
WO2006029046A3 (en) Use of leptin in wound healing
Poseryaev et al. METHODS OF CONSERVATIVE TREATMENT OF VENOUS TROPHIC ULCERS ON THE OUTPATIENT STAGE

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1461049

Country of ref document: EP